BACKGROUND AND AIMS: Hydrophobic bile acids contribute to hepatocellular injury in cholestasis and rapidly induce apoptosis in vitro; however, unlike Fas agonists, cholestasis does not cause extensive hepatocyte apoptosis. As antioxidants provide protection against bile acid induced liver injury, our premise was that bilirubin, a free radical scavenger with increased plasma levels in the presence of liver disease, could protect hepatocytes against bile acid induced apoptosis. METHODS: Freshly isolated rat hepatocytes were incubated for four hours with 100 micromol/l glycochenodeoxycholate (GCDC) alone or with increasing concentrations of unconjugated (UCB) or conjugated (CB) bilirubin. RESULTS: Both UCB and CB inhibited GCDC induced apoptosis in a dose dependent fashion and suppressed the generation of reactive oxygen species by hepatocytes. CONCLUSIONS: The antiapoptotic effect of bilirubin associated with its antioxidant properties indicates that hyperbilirubinaemia may have a protective role in liver disease.
BACKGROUND AND AIMS: Hydrophobic bile acids contribute to hepatocellular injury in cholestasis and rapidly induce apoptosis in vitro; however, unlike Fas agonists, cholestasis does not cause extensive hepatocyte apoptosis. As antioxidants provide protection against bile acid induced liver injury, our premise was that bilirubin, a free radical scavenger with increased plasma levels in the presence of liver disease, could protect hepatocytes against bile acid induced apoptosis. METHODS: Freshly isolated rat hepatocytes were incubated for four hours with 100 micromol/l glycochenodeoxycholate (GCDC) alone or with increasing concentrations of unconjugated (UCB) or conjugated (CB) bilirubin. RESULTS: Both UCB and CB inhibited GCDC induced apoptosis in a dose dependent fashion and suppressed the generation of reactive oxygen species by hepatocytes. CONCLUSIONS: The antiapoptotic effect of bilirubin associated with its antioxidant properties indicates that hyperbilirubinaemia may have a protective role in liver disease.
Authors: R J Sokol; M S Straka; R Dahl; M W Devereaux; B Yerushalmi; E Gumpricht; N Elkins; G Everson Journal: Pediatr Res Date: 2001-04 Impact factor: 3.756
Authors: C Hammerman; D Goldschmidt; M S Caplan; M Kaplan; R Bromiker; A I Eidelman; L M Gartner; A Hochman Journal: J Pediatr Gastroenterol Nutr Date: 2002-09 Impact factor: 2.839
Authors: Xiaoying Liu; Grace L Guo; Bo Kong; David B Hilburn; Susan C Hubchak; Seong Park; Brian LeCuyer; Antony Hsieh; Li Wang; Deyu Fang; Richard M Green Journal: Hepatology Date: 2018-05-10 Impact factor: 17.425
Authors: Pablo J Giraudi; Cristina Bellarosa; Carlos D Coda-Zabetta; Paolo Peruzzo; Claudio Tiribelli Journal: PLoS One Date: 2011-12-27 Impact factor: 3.240
Authors: Lucie Muchova; Katerina Vanova; Jaroslav Zelenka; Martin Lenicek; Tomas Petr; Martin Vejrazka; Eva Sticova; Hendrik Jan Vreman; Ronald James Wong; Libor Vitek Journal: J Cell Mol Med Date: 2010-05-28 Impact factor: 5.310
Authors: Elisabeth Lang; Sergios Gatidis; Noemi F Freise; Hans Bock; Ralf Kubitz; Christian Lauermann; Hans Martin Orth; Caroline Klindt; Maximilian Schuier; Verena Keitel; Maria Reich; Guilai Liu; Sebastian Schmidt; Haifeng C Xu; Syed M Qadri; Diran Herebian; Aleksandra A Pandyra; Ertan Mayatepek; Erich Gulbins; Florian Lang; Dieter Häussinger; Karl S Lang; Michael Föller; Philipp A Lang Journal: Hepatology Date: 2014-11-24 Impact factor: 17.425